Abstract: The present invention relates to methods of typing a female subject as being at risk of developing gestational diabetes, comprising determining a level of expression of Secreted Frizzled-Related Protein 4 (sFRP4). The invention further relates to methods of treating of a subject being at risk of developing, gestational diabetes, comprising typing the subject according to the methods of the invention, and treating the subject with a dietary meal plan and/or physical activity. The invention additionally relates to kit for a pregnant female subject for susceptibility to gestational diabetes, use of a kit according to the invention for typing a female subject as being at risk of developing gestational diabetes, and to an antibody specific to sFRP4 for use in a method for determining a risk of a female subject of developing gestational diabetes.

Abstract: The invention provides a biosensor for at least partial insertion in a fetal scalp, for monitoring an analyte in the body of the fetus, wherein the biosensor comprises a needle and a microdialysis element for sampling the analyte. The invention also provides a sensing system comprising the biosensor, configured to flow a liquid through the microdialysis element. The invention can be used for e.g. lactate sensing as well as releasing a pharmaceutical. Hence, the biosensor and/or sensing system may also be used for delivery of a pharmaceutical or nutrient to a fetus.

Abstract: A biosensor includes a biosensor unit with an electrode, wherein the electrode is rod-shaped, wherein the electrode further comprises a support with an electrically conductive first layer and an exclusion layer, wherein the electrically conductive first layer is configured between the support and the exclusion layer. A sensing system can include such biosensor.

Abstract: The invention provides a method for labeling an analyte comprising a primary amino group, the method comprising: a. a labeling process comprising reacting the analyte with a dialdehyde in the presence of a label, wherein the label bears a charge, and b. an analysis process comprising subjecting the labeled analyte to MS, preferably LC-MS-MS. Herein, preferably, the labeling process comprises reacting an analyte with a dialdehyde, wherein the dialdehyde carries a label bearing a charge, to provide a labeled analyte carrying the charge. The present invention also provides a labeling method to provide a labeled analyte carrying a charge, wherein the labeling method comprises a labeling process comprising reacting an analyte with a dialdehyde, wherein the analyte comprises a primary amino group and wherein the dialdehyde carries a label bearing the charge. The dialdehyde is preferably an aromatic dialdehyde, most preferably an aromatic 1,2- or 1,3-dicarboxaldehyde.

Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.

Abstract: An efficient pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkinson's disease, restless legs syndrome and erectile dysfunction. Said composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(?)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the base or the pharmaceutically acceptable salts or solvates thereof as an active ingredient in a pharmaceutical preparation suited for oral or intraduodenal administration.

Abstract: An efficient pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkin-son's disease, restless legs syndrome, male erectile dysfunc-tion and female sexual dysfunction is disclosed. Said composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the base or the pharmaceutically acceptable salts or solvates thereof as an active ingredient in a pharmaceutical prepara-tion suited for oral/intraduodenal administration.

Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.

Abstract: The present invention relates to the use of a combination of irindalone and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.